Business, energy, technology, markets and global industry news from Business News Today

GenTLE

PharmaDeviceNews GenTLE
A neurologist reviews brain MRI and EEG data as uniQure’s AMT-260 gene therapy is investigated as a potential one-time treatment for drug-resistant temporal lobe epilepsy. Representative image.
Pharma & Biotech

Can uniQure’s AMT-260 gene therapy become an alternative to epilepsy surgery?

Explore whether uniQure’s AMT-260 gene therapy can rival epilepsy surgery after early seizure reductions in a small first-in-human cohort.

Read More
Representative image of a neurology consultation with brain scan review, reflecting coverage of uniQure’s AMT-260 gene therapy data and its potential role in refractory mesial temporal lobe epilepsy treatment.
Pharma & Biotech

Why AMT-260’s early epilepsy data could shape the next test for brain-delivered gene therapy

Find out how uniQure’s AMT-260 early epilepsy data could shape the next test for brain-delivered gene therapy.

Read More